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Minireview: Functions of the renal tract epithelium in coordi-
nating the innate immune response to infection. Infection of
the urinary tract remains one of the most common infections
affecting mankind. Renal epithelial cells, being one of the first
cells to come into contact with invading organisms, are in a key
position to coordinate host defense. The epithelium not only
provides a physical barrier to infection, but can also augment
the immune response via the production of a number of inflam-
matory mediators and antimicrobial proteins.
Recent work has demonstrated that cells of the innate
immune system, including epithelial cells, express toll-like
receptors (TLRs), with the capacity to recognize bacterial com-
ponents. Although the exact mechanisms remain unclear, en-
gagement of TLRs can lead to epithelial cell activation and
the production of inflammatory mediators. These include com-
plement proteins, other bactericidal peptides, and chemotactic
cytokines. The resulting inflammatory infiltrate serves to aid
bacterial clearance, but can also lead to renal damage.
In this review, we describe how renal epithelial cells con-
tribute to the innate immune response to ascending urinary tract
infection. We specifically relate previous work to more recent
developments in this field. An improved understanding of the
mechanisms involved may highlight potential therapeutic av-
enues to aid bacterial clearance and prevent the renal scarring
associated with infection.
Urinary tract infections are one of the most common
bacterial infections affecting mankind. They are a major
cause of morbidity and mortality, with around 50% of
women being affected at one point in their lifetime [1],
and of these up to 36% will have a recurrent infection [2].
Pyelonephritis is a significant factor in the development
of end stage renal failure in children and young adults.
Although anatomic abnormalities, for example, reflux,
can be found in some patients with recurrent infection,
the majority have structurally and functionally normal
renal tracts. Therefore, the factors predisposing to recur-
Key words: renal epithelial cells, urinary tract infection, toll-like recep-
tors, complement, interleukin-8, defensins.
Received for publication October 29, 2003
and in revised form February 26, 2004, and May 7, 2004
Accepted for publication May 12, 2004
C© 2004 by the International Society of Nephrology
rent infection are not obvious in the majority of patients.
Treatment options are limited, and repeated courses of
antibiotics or long-term prophylactic treatment, which
may lead to the development of resistant strains, are often
required.
The gram-negative organism Escherichia coli is the
most common pathogen found in urinary tract infection,
being isolated in around 80% of cases [3] Uropathogenic
strains have been shown to have developed specific vir-
ulence factors, including hemolysin, adhesive fimbriae,
iron acquisition systems, and toxins [4]. A detailed dis-
cussion of these is beyond the scope of this article, but has
been reviewed elsewhere [5]. However, fimbriae deserve
a special mention. Fimbriae are thin hair-like projections
on the bacterial surface, which enable bacteria to attach
to the surface of uroepithelial cells, promoting coloniza-
tion. As well as mediating bacterial adherence, they have
also been shown to stimulate an inflammatory response
as described below. The critical role of P-fimbriae in the
pathogenesis of pyelonephritis has been described [6, 7]
and the importance of type 1 fimbriae in the invasion of
bladder epithelium has also been established [8]. How-
ever, although these virulence factors can help identify
those strains which are uropathogenic, they do not fully
explain the wide variation in clinical outcomes seen fol-
lowing bacteria entering the urinary tract.
The importance of the host response and particularly
the role of uroepithelial cells is now recognized [9]. The
ability of uroepithelial cells to produce cytokines in re-
sponse to bacteria and isolated fimbriae has previously
been described [10]. Studies have also identified the cor-
responding receptors on uroepithelial cells and signaling
pathways involved. For example, P fimbriae have been
shown to bind specific glycosphingolipids (GSL) recep-
tors which are abundant on uroepithelial cells [11]. This
leads to activation of the ceramide signaling pathway re-
sulting in the release of cytokines [12, 13]. The production
of specific cytokines influences local immunity, including
neutrophil influx and transmigration across the epithelial
cell barrier which is necessary for bacterial clearance [14].
These studies suggest that, rather than merely pro-
viding a physical barrier, renal epithelial cells play an
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important role in the local immune response, which in
turn may be an important determinant of clinical out-
come. Inadequate bacterial clearance may lead to recur-
rent infections or to a sustained inflammatory response
with subsequent scarring. Being at the interface between
the host and the exterior environment, epithelial cells are
in a key position to influence the outcome of infection.
The early response against invading pathogens is
provided by innate immunity. There are a number of
components of host innate immunity. These include phys-
ical elements such as the unidirectional flow of urine, the
barrier formed by the epithelial cells, and local produc-
tion of proteins to either trap bacteria (e.g., mucin) or
interfere with their ability to attach (e.g., Tamm-Horsfall
protein which binds type 1 fimbriae). More specific el-
ements of innate immunity include local production of
proteins, cytokines, and neutrophil recruitment. Further-
more, recent evidence suggests these more specific func-
tions can be tailored according to the type of invading
organism, a function previously thought to be exclusive
to acquired immunity. Our understanding of innate im-
mune mechanisms has recently undergone a major ad-
vance with the discovery of toll-like receptors (TLRs).
These are a series of germ-line encoded pattern recogni-
tion receptors which recognize conserved molecular pat-
terns on pathogens [15]. TLRs provide the elusive link
between recognition of invading organisms and develop-
ment of the innate immune response. Other components
of the innate immune response include the complement
system, scavenger cells (macrophages and neutrophils),
and the recently characterized defensins. All these play
a part in host defense and will be discussed individually.
However, it should be remembered that the overall re-
sponse is the result of the complex interplay between
a number of different bacterial molecules reacting with
their corresponding receptors on the cell surface.
Despite our present levels of knowledge, a number of
unanswered questions and controversies still exist. We
will integrate some recent advances in the field of innate
immunity with previous findings, focusing on the key role
of the renal epithelial cells as a coordinator of the inflam-
matory response. These advances may indicate means of
therapeutically manipulating the local response to shift
the balance in favor of bacterial clearance and reduced
host tissue damage. They may also have significant bear-
ing on other inflammatory conditions affecting the kid-
ney, where the role of epithelial cells is being increasingly
recognized.
TOLL-LIKE RECEPTORS
TLRs are a recently discovered family of receptors
that respond to preserved molecular motifs found on
pathogens, termed pathogen-associated molecular pat-
terns (PAMPs) [15]. They are the mammalian homo-
Table 1. Toll-like receptors (TLRs) and their ligands
Exogenous ligand Endogenous ligand Reference
TLR1 Mycobacterial
lipoprotein,
triacylated
lipopeptides
(cooperates with
TLR2)
[33, 40]
TLR2 ?Lipopolysaccharide
(LPS),
peptidoglycan,
lipoteichoic acid,
mycoplasmsal
proteins,
mycobacterial
proteins, zymosan,
spirochetes
(cooperates with
TLR1 and TLR6)
[33, 35, 41–45]
TLR3 Double-stranded
RNA
[46]
TLR4 LPS, taxol Heat shock protein
(HSP) 60 and 70,
heparin sulphate
[20, 21, 47–49]
TLR5 Flagellin [50]
TLR6 Diacylated
lipopeptides
(cooperates with
TLR2)
[51]
TLR7 Synthetic
imidazoquinolines,
single-stranded
RNA
[52, 53]
TLR8 Single-stranded RNA [53]
TLR9 CpG DNA [54]
TLR10 Unknown
TLR11 Unknown [39]
logues of the toll protein (dToll) found in the fruit fly,
Drosophila melanogaster. dToll was initially identified
as a critical protein in the embryologic development of
Drosophila, determining dorsoventral polarity [16]. It
was subsequently found to play an important part in
Drosophila’s primitive immune system, stimulating the
production of antifungal peptides in response to infection
[17]. Interestingly, unlike its mammalian homologues,
dToll does not recognize molecules on the pathogen di-
rectly, but binds with the peptide spaetzle, generated by
a protease cascade activated by the pathogen-associated
molecules [18].
To date, 11 mammalian TLRs have been identified, to-
gether with, in some cases, their corresponding ligands
(Table 1). They share a common structure consisting of an
extracellular domain of leucine-rich repeats, a transmem-
brane segment, and a cytoplasmic tail homologous to that
of the interleukin 1 receptor (IL-1R) [19]. The most stud-
ied of the TLRs is TLR4, which detects lipopolysaccha-
ride (LPS) found in the cell wall of gram-negative bacteria
such as E. coli, hence is potentially of importance in the
scenario of urinary tract infections.
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RECOGNITION OF LPS BY THE TLR4
SIGNALING COMPLEX
In 1998, genetic studies led to the identification of
TLR4 as the LPS signaling receptor, using naturally oc-
curring mutant mouse strains [20, 21]. C3H/HeJ mice had
long been known to be hyporesponsive to LPS [22]. A ma-
jor breakthrough came with the finding that this mouse
strain had a single point mutation of the lps gene, which
codes for TLR4, resulting in the substitution of histidine
for proline in the cytoplasmic tail and disrupted signal-
ing. A second mutant strain, C57BL/10ScCr, with a null
mutation of the lps gene, also demonstrated LPS hypore-
sponsiveness and these findings have now been confirmed
following the generation of TLR4 knockout mice [23].
However, TLR4 requires a number of accessory
molecules in order to signal a response, including CD14
and MD-2. CD14 enhances formation of the LPS recep-
tor complex but does not coprecipitate with it [24]. As
well as the membrane-bound form, CD14 also exists as a
soluble molecule (sCD14) at a plasma concentration of 2
to 6 lg/mL [25], allowing cells devoid of membrane bound
CD14 to still be responsive to LPS. A further plasma pro-
tein, LPS binding protein (LBP) is also involved in LPS
recognition by the TLR4 [26].
Another accessory molecule, MD-2 is required to-
gether with CD14 and TLR4 for cells to respond to LPS.
MD-2 is a secreted protein which associates with TLR4
on the cell surface, and has been shown to be necessary
for activation of intracellular signaling pathways follow-
ing LPS stimulation [27]. It also appears to play a part in
the cellular distribution of TLR4. In embryonic fibrob-
lasts from MD-2 knockout mice, TLR4 was shown to re-
side predominantly in the Golgi apparatus and unable to
reach the cell surface, where it is predominantly located
in these cells from wild-type mice [28].
Even this may be an oversimplification of the LPS
signaling complex. More recently a number of other
molecules have been implicated in the LPS recogni-
tion. These include the complement regulatory pro-
tein, decay accelerating factor (DAF) (CD55) [29] and
complement receptor 3 (CR3) (Mac-1) [30]. Triantafilou,
Triantafilou, and Dedrick [31], using fluorescence reso-
nance energy transfer (FRET), have demonstrated in-
teractions between a number of molecules during LPS
recognition, including heat shock proteins (HSP) 70
and 90, growth differentiation factor (GDF) 5, and the
chemokine receptor CXCR4 [31]. In many ways this is
analogous to signaling through the T-cell receptor com-
plex, where a number of molecules accumulate on the
cell surface in lipid rafts to form a receptor complex. In
evolutionary terms, there is good reason for us not to de-
pend upon pathogen recognition by a single molecule,
thus avoiding the situation where organisms would be
able to evade immune surveillance purely by avoiding
recognition by a solitary component. Our current under-
standing is that a number of molecules are involved in the
recognition of a PAMP, and that the nature and extent of
the host reaction will be a result of the exact receptor
complex formed [32]. Furthermore, the overall response
to a pathogen is dependent on complex interactions be-
tween a number of PAMPs on the pathogen and the cor-
responding receptor complexes on host cells.
OTHER TOLL-LIKE RECEPTORS
Studies using cell lines expressing TLR2 but not TLR4
and TLR2 knockout mice have demonstrated that TLR2
responds to a number of bacterial products from both
gram-positive and gram negative organisms, including
peptidoglycans [33], lipoteichoic acid (LTA) [34], and
mycoplasmal proteins [35]. Initial studies using over-
expression of TLR2 in cell lines suggested it played a
role in the response to LPS. However, repurification of
commercially available preparations of LPS eliminated
signaling in cells from C3H/HeJ mice [36]. The authors
also demonstrated that responsiveness to re-purified LPS
was conferred by transfection of TLR4, but not murine
or human TLR2. This suggests that the response to LPS
seen in previous studies may have been due to contami-
nation of the LPS with other bacterial products. Proteins
from some bacterial species are more potent stimula-
tors of TLRs than the corresponding protein from other
species. This has been shown in the case of LTA, where
LTA from Staphylococcus aureus was 100-fold more po-
tent in inducing tumor necrosis factor-a (TNF-a) pro-
duction from human peripheral blood mononuclear cells
than LTA from Streptococcus pneumoniae. Heterodimer-
ization between some TLRs also occurs, potentially in-
creasing the diversity of PAMPs that can be recognized
[37, 38]. TLR11, the most recent TLR to be described,
showed greatest expression in the kidney compared with
other tissues. Although the ligands for TLR11 are as yet
unknown, mice lacking TLR11 were shown to be highly
susceptible to infection of the kidneys following inocu-
lation with uropathogenic bacteria, suggesting it plays a
role in preventing pyelonephritis [39].
The ligands for a number of other TLRs have also been
identified (Table 1).
TOLL-LIKE RECEPTOR SIGNALING
Studies in macrophages have revealed some of the in-
tracellular signaling pathways activated by TLRs. One
pathway utilizes the adaptor protein MyD88 leading to
translocation of the nuclear factor-kappaB (NF-jB) and
activation of activating protein-1 (AP-1) transcription
factors, which in turn leads to production of proinflam-
matory cytokines [19]. This pathway is thought to be
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Fig. 1. A number of soluble serum and cell surface molecules are in-
volved in the recognition of lipopolysaccharide (LPS). The LPS/LPS
binding proteins (LBP) complex is delivered by CD14 to the TLR4/MD-
2 receptor complex on the cell surface. This leads to recruitment of
specific adaptor proteins to the intracellular tail of TLR4, termed the
toll/interleukin (IL-1) receptor (TIR) domain. Pathway 1 using MyD88
is common to all TLRs and the IL-1 receptor. Pathway 2 uses alternative
adaptor proteins and appears specific to certain TLRs. These pathways
lead to activation of nuclear factor-jB (NF-jB) and activating protein-
1 (AP-1) transcription factors, which in turn leads to the production
of a number of proinflammatory cytokines and antimicrobial proteins.
The subset of genes induced differs depending upon which of the above
pathways is activated, allowing some tailoring of the response.
common to all TLRs and has been termed the “core”
TLR response. In the case of certain TLRs, including
TLR4, a second MyD88 independent pathway has been
demonstrated which results in a different subset of genes
being induced [55–57], allowing some tailoring of the re-
sponse (Fig. 1). At present, little is known about TLR
signaling in renal epithelial cells. Studies using murine
proximal tubular epithelial cells have shown the presence
of CD14, MD-2, MyD88, and MAL. Furthermore, C-C
chemokine production in response to LPS was found to
be NF-jB-dependent [58]. However, Frendeus et al [59]
found that the GSL receptors for P-fimbriae recruited
TLR4 as a coreceptor in cell signaling. As previously men-
tioned, cytokine production in response to P-fimbriated
bacteria has been shown to occur as a result of activation
of the ceramide signaling pathway. Therefore, one pos-
sibility is that the signaling pathways activated by TLRs
differ depending on the type of cell in question. This is im-
portant when interpreting our present understanding of
TLRs, which is largely based on studies in macrophages
and other professional immune cells.
TOLL-LIKE RECEPTORS AND RENAL
EPITHELIAL CELL FUNCTION
The functional role of TLRs, specifically in urinary tract
infection, has been examined in human cells and mouse
models, with conflicting results. Ba¨ckhed et al [60] ex-
amined the response of human kidney (A498) and blad-
der (T24) epithelial cell lines in response to stimulation
with whole bacteria and LPS [60]. Stimulation with E.
coli strain W3110, which express type1 fimbriae, resulted
in increased IL-8 production in both cell lines, although
the bladder cell response was markedly greater. Inter-
estingly, blocking of type 1 fimbrial attachment to the
cells using mannose only affected IL-8 production from
renal epithelial and not bladder cells. Following stimula-
tion with different commercial preparations of LPS, renal
epithelial cells failed to demonstrate any increase in ei-
ther IL-6 or IL-8 production, in contrast to the bladder
cell line. The response to LPS correlated with the pres-
ence of TLR4 and CD14, which were not found on the
renal epithelial cell line. Isolated renal proximal tubu-
lar epithelial cells expressed only TLR3 and TLR5, al-
though TLR4 was present in whole kidney isolates. The
authors hypothesized that this was a result of passen-
ger macrophages within the kidney. However, Frende´us
et al [59], also using the same A498 human cell line, were
able to identify the presence of TLR4, both at a genetic
and protein level. Despite this observation, they demon-
strated that cytokine production by these cells in vitro
was related to presence of P-fimbriae and not affected by
bacterial LPS status [61]. Addition of serum to provide
a source of exogenous CD14 also failed to confer LPS
responsiveness. This contrasts with activation of uroep-
ithelial cells by type 1 fimbriae which appears to be LPS
and TLR4-dependent [62]. It is not clear how represen-
tative these in vitro observations using a cell line are of
the responses in vivo.
ANIMAL STUDIES OF TLR4 FUNCTION
In contrast to studies with human cell lines, work in
murine models appears to demonstrate a key role for
TLR4 and LPS in the immune response by renal epithelial
cells.
As previously mentioned, expression of some of
the molecular machinery for TLR4 signaling has been
demonstrated in renal epithelial cells. Constitutive ex-
pression of CD14 has been demonstrated within the
kidney, and immunohistochemistry revealed that this
1338 Chowdhury et al: Renal tract epithelium and immune response to infection
was located both within and on the surface of tubu-
lar epithelial cells. In noninfectious models of inflam-
mation as a result of unilateral ureteric obstruction
or ischemia/reperfusion, induction of CD14mRNA was
seen in a number of different mouse strains, including
C3H/HeJ, and this is regulated via TNF-a acting through
TNF receptor 1 [63]. Expression of both TLR2 and TLR4
within the mouse kidney has been demonstrated using in
situ hybridization, the majority of which was located in
renal epithelial cells [64].
The role of these molecules has further been examined
in vivo. It has long been known that following intravesi-
cal inoculation of virulent E. coli strains, C3H/HeJ mice
fail to clear bacteria and are susceptible to urinary tract
infection [65]. Susceptibility was shown to relate to a ge-
netic defect in the C3H/HeJ strain rendering them hy-
poresponsive to LPS and further studies demonstrated
impaired neutrophil recruitment into urine following bac-
terial inoculation, underlying the key importance of neu-
trophils in maintaining sterility of the renal tract [66, 67].
The identification of the defective gene product as TLR4
has shed new light on these original findings, and suggests
an important role for TLR4 in neutrophil recruitment and
the response to bacteria within the urinary tract.
Using C3H/HeJ strain mice, Frende´us et al [59] showed
that the response to P-fimbriaeted E. coli in vivo was
TLR4-dependent. The constituent of LPS responsible for
cell activation has been shown to be the lipid A moiety.
Using a mutated bacterial strain with inactivated lipid A,
this same group showed that TLR4-dependent P-fimbrial
activation was not affected by lipid A status, suggesting
LPS-independent TLR4 signaling. However, the readout
in this experiment was not cytokine production, but neu-
trophil migration into the kidney, which although related
to chemokine production by local cells, may be influenced
by a number of other factors.
More recently, Tsuboi et al [58] confirmed the ex-
pression of TLR4 at a gene level in primary cultures
of murine tubular epithelial cells. The level of expres-
sion was found to be similar to that seen in the mouse
macrophage cell line RAW 264.7. Furthermore, these
cells demonstrated increases in messenger RNA of the
chemokines RANTES and monocyte chemoattractant
protein-1 (MCP-1) following LPS stimulation. They also
stimulated primary cultures of murine tubular epithelial
cells from C3H/HeJ and C3H/HeN controls with a syn-
thetic lipid A derivative, and found that chemokine pro-
duction was TLR4-dependent. This latter study therefore
suggests that murine proximal tubular cells do respond to
LPS via TLR4.
Although specifically focusing on the bladder epithe-
lium, Schilling et al [68] recently used a bone marrow
chimera model to investigate the separate roles of TLR4
on stromal compared with hemopoietic cells in vivo. They
found that TLR4 on epithelial cells was required to clear
bacteria from the bladder during acute infection. How-
ever, induction of the inflammatory response was largely
dependent on TLR4 being present on hemopoietic cells.
The authors hypothesize TLR4 on uroepithelial cells may
not be necessary to initiate the inflammatory response,
but is required in its augmentation with the production
of cytokines and antimicrobial peptides.
In summary, controversy still exists in the human set-
ting as to the contribution of LPS stimulating TLR4 on
renal epithelial cells in the generation of a local im-
mune response. The story is less controversial in mice,
where renal epithelial cells have been shown to express
the molecular machinery for TLR4 signaling, and studies
have demonstrated its role in cytokine production follow-
ing stimulation with LPS.
THE COMPLEMENT SYSTEM
The complement system consists of a series of plasma
proteins and cell surface regulatory proteins and recep-
tors. Activation of the complement cascade occurs via
three distinct pathways, namely the classical, alterna-
tive, and mannan-binding lectin (MBL) pathways, all of
which can be activated by invading organisms. Activa-
tion via any of these pathways leads to formation of a
C3 convertase and the splitting of C3, a central point of
convergence. This subsequently leads to activation of the
terminal pathway which culminates in formation of the
membrane attack complex C5b-9, which can directly lyse
susceptible bacteria. A number of split products of com-
plement components are also formed from the cascade,
including C3a, C3b, iC3b, C3d, C4b, and C5a, which have
been shown to have immunomodulatory properties via
interaction with cell surface receptors. The anaphylotox-
ins C3a and C5a are of importance in neutrophil chemo-
taxis, while covalently bound C3 fragments have been
shown to increase sensitivity of the immune response via
opsonization of antigen and subsequent interaction with
complement receptor 2 (CR2) on immune cells [69]. A
low level of spontaneous activation of complement nor-
mally occurs and to prevent damage to host cells, a num-
ber of cell surface and soluble complement regulators
exist. These not only inhibit complement activation at
various points in the cascade but act as the cellular recep-
tor to several pathogens.
LOCAL COMPLEMENT PRODUCTION WITHIN
THE KIDNEY
Although the majority of circulating complement is
produced by the liver, a number of extrahepatic tissues
have been shown to be capable of producing complement
components. In the case of the kidney, glomerular epithe-
lial [70], mesangial [71, 72], and endothelial cells [73] are
all capable of local complement production. Brooimans
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et al [74] has also demonstrated the synthesis of comple-
ment components by human proximal tubular epithelial
cells, and in situ hybridization studies have shown tubu-
lar epithelial cells to be a prominent site of complement
gene expression in both normal and diseased kidneys [75,
76].
The contribution of renal complement production has
been examined in patients who have undergone renal
transplantation. Tang et al [77] specifically studied those
in whom the C3 isotype of the donor differed from that
of the recipient. In the stable state, donor C3 contributed
4.5% to the total pool, rising to 9.6% during episodes of
rejection.
The production of complement by proximal tubular
cells can be up-regulated in vitro by a number of in-
flammatory cytokines including IL-1a, IL-2, TNF-a, and
interferon-c (IFN-c), while transforming growth factor-b
(TGF-b) reduces expression of the C3 and C4 compo-
nents [78–81]. The addition of serum proteins to the api-
cal surface of proximal tubular cells also increases C3
production, and interestingly switches secretion from
a predominantly apical to a basolateral direction [82].
Furthermore, regulation of complement components
demonstrates tissue-specific regulation, with IL-1 and en-
dotoxin causing up-regulation of C2 gene expression in
the kidney but not the liver [83].
LOCAL COMPLEMENT SYNTHESIS AND
RENAL DISEASE
A pathogenic role for local complement production
has been proposed in a number of inflammatory condi-
tions affecting the kidney, including glomerulonephritis
[76, 84–86], allograft rejection [87, 88], and infection [89].
A marked increase in mRNA for C3 and C4 in the kid-
ney has been noted to coincide with the development of
glomerulonephritis and proteinuria in rodent models of
immune complex disease, such as lupus nephritis [86]. In
renal transplantation, increased C3 mRNA expression
was seen in biopsies with evidence of cellular rejection
and levels of this local expression correlated with graft
loss and eventual outcome [87]. In a mouse transplan-
tation model, recipients of a C3-deficient kidney were
shown to have markedly increased graft survival com-
pared with those who received organs from C3-sufficient
congenic controls [88]. Increased survival was not seen if
wild-type grafts were transplanted into C3-deficient re-
cipients, confirming the importance of local complement
synthesis. Histologic analysis revealed graft loss in the
wild-type group was due to cellular rejection and analy-
sis of C3 gene expression showed an increase which was
localized to the cortical tubules.
Increases in local complement production have been
shown to occur during infections in nonrenal organs, for
example, in mastitis and meningitis [90, 91]. In the renal
Table 2. Complement components exploited by pathogens to
facilitate tissue invasion
Complement
inhibitor/receptor Natural ligand Pathogen
CR1 C3b, C4b Plasmodium falciparum [92];
opsonized Mycobacterium
leprae [93]
CR2 C3d, C4d Epstein-Barr virus [94]
CR3 iC3b Opsonized Mycobacterium
tuberculosis [95]; opsonized
Mycobacterium leprae [93]
CR4 Opsonized Mycobacterium
leprae [93]
Membrane cofactor
protein (CD46)
C3b, C4b Measles virus [96]; human
herpes virus 6 [97]; Neisseria
gonorrhea [98]; b-hemolytic
Streptococci [99]
Decay accelerating
factor (CD55)
C3b Dr fimbrial expressing,
uropathogenic Escherichia
coli [100]; picornaviruses [101]
tract, urinary C3 levels increase 400-fold following de-
velopment of infection in mice [89]. Although some of
this may represent an overspill from the systemic pool, at
least a part is likely to be a consequence of increased local
production. In support of the latter, in vitro cultures of
murine proximal tubular epithelial cells increase C3 pro-
duction sixfold following stimulation of LPS. Also C3,
being a large molecule (185,000 kD), is unlikely to be fil-
tered across the undamaged glomerular membrane. The
functional significance of this production has been exam-
ined in vivo by Springall et al [89], revealing somewhat
unexpected results. Following inoculation of E. coli into
the bladder, C3- and C4-deficient mice demonstrated less
bacterial invasion of the kidney compared with wild-type
controls. This was further investigated in vitro, where it
was found that opsonization of bacteria with C3 assisted
their invasion of the epithelial cell monolayer. The au-
thors postulated that invasion was assisted by the inter-
action between C3-opsonized bacteria and complement
receptors located on the renal epithelial cell surface. In-
hibition of the interaction between epithelium and C3b
(a split product of C3) with soluble complement inhibitor
Crry resulted in a reduction in bacterial internalization.
A number of complement receptors do exist in humans,
and several pathogens have been shown to use these to
assist invasion of cells (Table 2). Both decay accelerating
factor (CD55) and membrane cofactor protein (CD46)
have been located on the surface of human renal epithe-
lial cells. With the exception of Dr fimbriated E. coli bind-
ing to CD55, no specific function has been demonstrated
for these molecules in urinary tract infections. These ob-
servations illustrate the complex, occasionally paradoxic
role, for complement in urinary tract infections on the
one hand able to provide defense against infection but
on the other also assisting bacterial invasion.
1340 Chowdhury et al: Renal tract epithelium and immune response to infection
Bacteria
LBP
LPS
LPS
CD14 MD2
PG
MyD88
C3 b
C3 b
1 2
3
? ?
Tubular lumen
β defensins
Complement
proteins
NFκB Transcriptionfactors
Tubular
epithelial
cell
α-defensins
ROSProteases
IL8 MCP RANTES Defensins Mφ
lymphocytes
Adaptive
response
Capillary lumen
Transcriptional
activation
Fig. 2. The renal tubular epithelial cell lies central in the early re-
sponse to tubular infection. Bacteria interact with tubular epithelial
cells through at least three systems. 1, Lipopolysaccharide (LPS) (sol-
uble or on the bacterial surface) or proteoglycan (PG) signal through
toll-like receptors (TLRs) on the epithelium. 2, Bacterial adhesins bind
to molecular motifs on the epithelial cell surface. 3, Complement op-
sonized bacteria can interact with complement binding proteins (CD46
and CD55) on the epithelium. These interactions transduce an intracel-
lular signal through nuclear factor-jB (NF-jB) and other transcription
factors that lead to an up-regulation of proinflammatory and antimicro-
bial gene expression. The proteins produced coordinate other immune
effector mechanisms, both innate and adaptive, that lead to pathogen
clearance.
NEUTROPHILS AND CHEMOKINES
Neutrophils are key effector cells of the innate immune
system, and influx of neutrophils into the kidney is impor-
tant in the clearance of infection. Neutrophil depletion
has been shown to render normal mice susceptible to uri-
nary tract infections [102]. Cytoplasmic granules within
neutrophils contain a number of antimicrobial products,
including defensins, bactericidal/permeability increasing
(BPI) factor, and cathepsin G. Following phagocytosis
these granules fuse with the phagosome leading to killing
of the invading organism. However, as well as assisting
with bacterial clearance, the ensuing inflammatory re-
sponse can lead to damage of host tissues.
During urinary tract infection, neutrophils migrate
through the capillary walls to reach the epithelial cell
layer, which they then cross in order to interact with
organisms within the tubular lumen. Local production
of chemokines is of fundamental importance in this mi-
gration process [103]. Chemokines are divided into four
families based on the position of the first two cysteine
residues in the amino acid sequence [104]. The CXC
chemokines are thought to be mainly involved in neu-
trophil recruitment to sites of inflammation, while CC
chemokines exhibit a broader target cell specificity in-
cluding macrophages and lymphocytes.
Godaly et al [105] have shown that human renal ep-
ithelial cells secrete chemokines in response to infec-
tion with E. coli, and IL-8 was identified as the main
chemokine involved in transepithelial neutrophil mi-
gration in vitro. Two murine homologues of IL-8 have
been identified, namely KC and macrophage inflamma-
tory protein-2 (MIP-2) [106]. These chemokines mediate
their effects via interaction with cell surface receptors.
In humans, two IL-8 receptors have been characterized,
CXCR1 and CXCR2, whose genes lie on chromosome
2q35 [107]. CXCR1 shows greater specificity binding IL-
8 and granulocyte chemotactic protein, while CXCR2
binds a number of CXC chemokines. In contrast, mice
only express one CXC chemokine receptor (mIL-8R)
which binds both KC and MIP-2.
Godaly et al [108] have demonstrated expression of
CXCR1 and 2 on bladder and renal epithelium obtained
from human biopsy samples. In contrast, the A498 hu-
man kidney epithelial cell line was found to be receptor
negative by confocal microscopy. However stimulation
with E. coli–induced expression of both CXCR1 and 2,
as detected by flow cytometry. This was shown to cor-
respond with increased IL-8 binding, which was inhib-
ited using anti-CXCR1, but not anti-CXCR2 antibodies.
The in vivo relevance of these findings was examined us-
ing mIL-8R knockout mice. Following intravesical inoc-
ulation of E. coli, these mice demonstrated a delay in
neutrophil recruitment to the bladder epithelium. Fur-
thermore, in the knockouts, the neutrophils accumulated
in the subepithelial layer and were not able to cross into
the tubular lumen. IL-8R knockout mice developed bac-
teremia and were sicker than the control mice that read-
ily cleared infection. Thus as well as a primary role in
neutrophil recruitment, local actions of chemokines may
also involve acting on epithelium to allow passage of neu-
trophils through it. These findings have been extended to
the clinical setting where children prone to pyelonephri-
tis showed reduced CXCR1 expression compared with
aged-matched controls [109].
DEFENSINS IN THE KIDNEY
The defensins are a group of small (2 to 6 kD), highly
cationic antimicrobial peptides produced by a variety
of mammalian cells [110]. The defensins are character-
ized by three sulphydryl bonds between highly conserved
cysteine residues. They fall into three groups based upon
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their molecular structure. The a-defensins are synthe-
sized mainly, though not exclusively, by neutrophils and
the cyclical h-defensins by phagocytes in primates but not
humans. In humans, four b-defensins have so far been
described (b-defensin 1 to 4), synthesized mainly by ep-
ithelial cells including those of the bronchial tree, gas-
trointestinal tract, skin, and the renal tract.
Within the kidney the b-defensins are produced by ep-
ithelial cells in the loop of Henle, distal convoluted tubule,
and collecting duct [111]. In humans b-defensin-1 is pro-
duced in the kidney constitutively at a higher level (up to
20-fold) than in other tissues examined [112]. b-defensin-
2 and -3 are produced after exposure to pathogens or
proinflammatory cytokines [113, 114], although the fac-
tors that regulate renal synthesis are not well understood.
b-defensin-1 can be detected in the urine at a concentra-
tion of 10 to 100 lg/L [111] and this concentration can
increase by up to threefold during pyelonephritis [115],
reflecting either increased synthesis or release from dam-
aged cells. The concentration of b-defensin-1 achieved
even during infection is below that required for anti-
microbial activity in vitro (1 to 10 lg/mL), however, this
does not exclude activity at a local tissue level where
higher concentrations may be achieved. Indeed, the ca-
pacity of the renal epithelium to produce defensins at a
bactericidal concentration has been clearly shown in vitro
[116].
During renal tract infection the innate response will
include both b-defensins from the local epithelium and
a-defensins from infiltrating neutrophils. All of the de-
fensins have antimicrobial activity and are able to kill
bacteria, fungi, and some encapsulated viruses. Struc-
turally they contain both hydrophobic and cationic
domains. The hydrophic domain inserts into the cell mem-
brane of pathogens and the cationic domain interacts with
anionic residues on the pathogen surface. They show se-
lectivity for the cell membranes of pathogens because of
the absence of cholesterol and the high concentration of
anionic phospholipids. The presence of defensins within
the membrane disrupts membrane function increasing
permeability and causing cell death [117]. Although some
defensins can aggregate and form pore-like structures the
exact mechanism by which they disrupt membrane func-
tion is unknown. The antimicrobial activity of a- and b-
defensins is greatest at low salt concentrations and they
are only weakly antimicrobial in physiologic conditions.
Therefore, their antimicrobial activity may be confined
to intracellular compartments in phagocytes in which low
salt concentrations are achieved or at epithelial cell sur-
faces. In the kidney the activity of b-defensins will vary
along the distal nephron as the salt concentration varies
and will be influenced by other factors such as hydration
status.
In addition to their antimicrobial activity defensins
may also influence the immune and inflammatory re-
sponse in other ways (reviewed by Yang et al [118]).
They may augment innate responses by causing mast cell
degranulation and promoting neutrophil chemotaxis by
increasing IL-8 production. They can also enhance or in-
hibit the activation of the classic pathway of complement
by binding to C1q. In addition, defensins can also influ-
ence adaptive immune responses, clearly demonstrated
by their ability to act as adjuvants, increasing humoral and
cellular responses to administered antigen. Both a- and
b-defensins are chemoattractant for T cells and imma-
ture dendritic cells, with the b-defensins acting through
the CC chemokine receptor CCR6. This suggests some
degree of functional overlap, although no sequence ho-
mology, between the defensins and the chemokines. This
relationship is further supported by the observation that
chemokines can also have antimicrobial activity. Addi-
tional overlap in these systems is illustrated by the ability
of murine b-defensin-2 to activate signaling for dendritic
cell maturation through TLR4 [119].
CONCLUSIONS
Bacteria are constantly evolving to avoid elimination
by host defense mechanisms and antibiotics. Therefore
we must continue to improve our understanding of the
mechanisms of infection so that we can develop new
strategies to combat the ongoing threat. The recent ad-
vances in innate immunity have provided new insights
into the interaction between host and pathogen, which
may impact on clinical practice. For example, studies in
patients with gram-negative septic shock have revealed
that certain polymorphisms in the TLR4 gene may pre-
dispose patients to more severe disease [120]. Polymor-
phisms in a number of other candidate genes may also
be involved in determining those patients who are pre-
disposed to a worse outcome following infection. These
include the genes for proinflammatory cytokines such as
TNF-a and those encoding components of the comple-
ment system such as C3 and factor B. Identification of
susceptible individuals may allow treatment to be tailored
to their specific needs.
In the case of ascending urinary tract infection, re-
nal epithelial cells are at the interface between organ-
isms and the host. Local events as a result of the inter-
action between these cells and pathogens appear to be
an important determinant of the overall clinical outcome
(Fig. 2). Furthermore, they may hold the explanation as
to why certain individuals are susceptible to recurrent
infections and possibly why some patients, particularly
children, develop progressive renal impairment as a re-
sult. In addition, a number of similarities exist between
the inflammatory reaction during infection, and a number
of other noninfectious diseases affecting the tubulointer-
stitial compartment, including transplant rejection and
proteinuria-related fibrosis. A better understanding of
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the innate immune response during infection may there-
fore provide insight into the pathophysiology and treat-
ment of these diverse and important diseases.
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